CYTEK BIOSCIENCES, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $201.5M | $200.5M | $193.0M | $3.0M | $2.2M | $710.0K |
| Cost of Revenue | — | $97.0M | $89.3M | $83.6M | $63.1M | $48.8M | $41.1M |
| Gross Profit | — | $104.5M | $111.1M | $109.4M | $101.0M | $79.1M | $51.7M |
| Gross Margin | — | 51.8% | 55.4% | 56.7% | 3,407.8% | 3,628.8% | 7,283.1% |
| Operating Expenses | |||||||
| Research & Development | — | $36.5M | $39.4M | $44.2M | $34.9M | $24.4M | $13.7M |
| SG&A Expense | — | $58.9M | $43.1M | $44.0M | $34.7M | $20.8M | $9.4M |
| Operating Income | — | $-40.4M | $-20.5M | $-27.8M | $-1.8M | $9.2M | $13.7M |
| Operating Margin | — | -20.0% | -10.2% | -14.4% | -60.9% | 419.9% | 1,923.8% |
| Interest Expense | — | — | — | $2.1M | $2.6M | $1.7M | $333.0K |
| Pretax Income | — | $-29.8M | $-5.7M | $-15.7M | $1.3M | $5.9M | $14.4M |
| Income Tax Expense | — | $36.7M | $320.0K | $-3.6M | $-1.2M | $2.9M | $-5.0M |
| Net Income | — | $-66.5M | $-6.0M | $-12.1M | $2.5M | $3.0M | $19.4M |
| Net Margin | — | -33.0% | -3.0% | -6.3% | 83.8% | 138.8% | 2,733.9% |
| EPS (Basic) | — | $-0.52 | $-0.05 | $-0.09 | $0.02 | $0.00 | $0.04 |
| EPS (Diluted) | — | $-0.52 | $-0.05 | $-0.09 | $0.02 | $0.00 | $0.03 |
| Shares Outstanding (Basic) | 128.6M | 127.7M | 130.6M | 135.3M | 134.5M | 76.7M | 87.4M |
| Shares Outstanding (Diluted) | 128.6M | 127.7M | 130.6M | 135.3M | 138.6M | 81.5M | 97.8M |
| Dividends Per Share | — | — | — | — | — | — | — |